| To view this email as a web page, click here.
|
Volume VII ▪ Issue V
OncLive®, An MJH Life Sciences™ brand ▪ Est. MCMXCIX |
 |
| Good morning. From our global headquarters in New Jersey, OncLive® delivers the resources and information oncology professionals need to provide the best patient care. In this edition, 2 BTK inhibitors go head-to-head in a CLL trial, while 2 novel checkpoint inhibitors move through the pipelines in esophageal cancer and mucosal melanoma. |
| |
|
| You can follow us here for breaking news on new drug approvals, updates on upcoming events, and new insights from the leading voices in Oncology. |
| |
| Thanks for your continuing support. |
| |
| G. MAURO |
| Editorial Director, OncLive® |
| |
| Image: 375x180 px |
| Headline |
| First sentence of story. No more than two lines in this space... |
| Read More |
|
| Image: 375x180 px |
| Headline |
| First sentence of story. No more than two lines in this space... |
| Read More |
|
| Image: 375x180 px |
| Headline |
| First sentence of story. No more than two lines in this space... |
| Read More |
|
|
| Image: 375x180 px |
| Headline |
| First sentence of story. No more than two lines in this space... |
| Read More |
|
| Image: 375x180 px |
| Headline |
| First sentence of story. No more than two lines in this space... |
| Read More |
|
| |
